StockData
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. (PRQR) stock

PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 7/30
$1.15−0.03 (-2.54%)

Close on Nov 17, 2026Market cap $121.17MP/E –Yield –

ProQR Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

ProQR Therapeutics's total debt was €5.02M at Jun 30, 2026. For fiscal 2025 it was €4.87M, up 6.3% from the year before. The highest annual figure on record is €44.09M in fiscal 2021.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025€4.87M+6.3%
FY2024Dec 31, 2024€4.58M+6.8%
FY2023Dec 31, 2023€4.29M-36.6%
FY2022Dec 31, 2022€6.77M-84.6%
FY2021Dec 31, 2021€44.09M+138.9%
FY2020Dec 31, 2020€18.46M+41.4%
FY2019Dec 31, 2019€13.05M+39.1%
FY2018Dec 31, 2018€9.39M+29.6%
FY2017Dec 31, 2017€7.24M+27.2%
FY2016Dec 31, 2016€5.70M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€5.02M+6.1%
Q1 FY2026Mar 31, 2026€4.95M+6.2%
Q4 FY2025Dec 31, 2025€4.87M+6.3%
Q3 FY2025Sep 30, 2025€4.80M+6.4%
Q2 FY2025Jun 30, 2025€4.73M+6.5%
Q1 FY2025Mar 31, 2025€4.66M+6.6%
Q4 FY2024Dec 31, 2024€4.58M+6.8%
Q3 FY2024Sep 30, 2024€4.51M-13.8%
Q2 FY2024Jun 30, 2024€4.44M-31.7%
Q1 FY2024Mar 31, 2024€4.37M-32.6%
Q4 FY2023Dec 31, 2023€4.29M-36.6%
Q3 FY2023Sep 30, 2023€5.24M-21.4%
Q2 FY2023Jun 30, 2023€6.50M-85.6%
Q1 FY2023Mar 31, 2023€6.48M-85.5%
Q4 FY2022Dec 31, 2022€6.77M-84.6%
Q3 FY2022Sep 30, 2022€6.66M-65.5%
Q2 FY2022Jun 30, 2022€44.99M+142.7%
Q1 FY2022Mar 31, 2022€44.76M+142.5%
Q4 FY2021Dec 31, 2021€44.09M+151.6%
Q3 FY2021Sep 30, 2021€19.30M+247.5%
Q2 FY2021Jun 30, 2021€18.53M+35.8%
Q4 FY2020Dec 31, 2020€18.46M+41.4%
Q3 FY2020Sep 30, 2020€17.53M+62.7%
Q2 FY2020Jun 30, 2020€5.56M-47.3%
Q1 FY2020Mar 31, 2020€13.65M+45.4%
Q4 FY2019Dec 31, 2019€13.05M+62.7%
Q3 FY2019Sep 30, 2019€10.77M+48.7%
Q2 FY2019Jun 30, 2019€10.54M+84.9%
Q4 FY2018Dec 31, 2018€9.39M–
Q2 FY2018Jun 30, 2018€8.02M–
Q4 FY2017Dec 31, 2017€7.24M–
Q4 FY2016Dec 31, 2016€5.70M–

More ProQR Therapeutics figures

See a number that looks wrong?